Barclays analyst Peter Lawson raised the firm’s price target on MacroGenics to $25 from $23 and keeps an Overweight rating on the shares following the Q4 report. The firm says the company’s cash runway was reiterated into 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MGNX:
- MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
- MacroGenics price target raised to $24 from $12 at BTIG
- MacroGenics to Participate in Upcoming Investor Conferences
- MacroGenics price target raised to $23 from $12 at Barclays
- MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
